Arbutus Biopharma (ABUS) Debt Ratio (2016 - 2017)

Arbutus Biopharma (ABUS) posted Debt Ratio of 0.05 for Q4 2017, up 1.13% sequentially from 0.05 in Q3 2017, and up 16.34% YoY from 0.04 in Q4 2016.

Arbutus Biopharma (ABUS) Debt Ratio (2016 - 2017) Analysis & Trends

Arbutus Biopharma has reported Debt Ratio for 2 years, with the latest figure at 0.05 in Q4 2017.

Quarterly Debt Ratio rose 16.34% year-over-year to 0.05 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was 0.05 (up 16.34% YoY) and the FY2017 annual result came in at 0.05, up 16.34% from the prior year.
Debt Ratio advanced to 0.05 in Q4 2017 per ABUS's latest filing, from 0.05 in the prior quarter.
Over five years, Debt Ratio peaked at 0.05 in Q4 2017 and troughed at 0.04 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Arbutus Biopharma	922.95 Mn	830.33 Mn	-	-

Download Data